Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
Helus Pharma has added Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board as it advances its pipeline of novel serotonergic agonists for mental health disorders. The additions reflect the company's focus on grounding innovation in robust clinical evidence.
Helus Pharma has strengthened its Scientific Advisory Board with the addition of Dr. Robert Langer and Dr. Stephen Brannan. The company's Scientific Advisory Board supports its commitment to advancing its pipeline through disciplined drug development and scientific rigor. Dr. Langer is a world-renowned leader in biotechnology and drug delivery, while Dr. Brannan is a physician-scientist with expertise in CNS therapeutics. Helus Pharma is developing novel serotonergic agonists, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder. The additions to the Scientific Advisory Board reflect the company's continued focus on grounding innovation in robust clinical evidence.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.